TriSalus Life Sciences, Inc. (TLSI) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.67

From 52W high−52.93%

Volume106263.00

Market cap$217.36M

P/E (TTM)—

P/S (TTM)4.8x

Div yield—

Key dataOct 19, 2026

Open

$3.67

From 52W high

−52.93%

Volume

106263.00

Market cap

$217.36M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.5x

P/E (TTM)

—

RSI (14)

25.8

MomentumView details →

1D Return

−2.75%

YTD Return

−48.57%

SummaryUpdated Jun 1, 2026

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a medical device and immunotherapy company founded in 2017 and based in Westminster, Colorado. The company went public in February 2021 and specializes in developing innovative treatment technologies for liver and pancreatic cancers. TriSalus has established itself as a pioneer in pressure-enabled drug delivery (PEDD) technology, which allows for more targeted and effective treatment of solid tumors through specialized infusion systems.

Ask drillr about TriSalus Life Sciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.5x

EV/Sales

4.6x

P/S (TTM)

4.8x

P/B (TTM)

33.2x

ProfitabilityView details →

Gross Margin

85.79%

Net Margin

−62.59%

EBITDA Margin

−48.06%

ROE (TTM)

−430.72%

ROA (TTM)

−45.18%

Asset Turnover

0.68x

GrowthView details →

Revenue YoY

+25.25%

EPS YoY

−9.24%

FCF YoY

−2.22%

Revenue CAGR 3Y

+53.85%

EPS CAGR 3Y

−47.20%

EBITDA YoY

+15.47%

MomentumView details →

1D Return

−2.75%

YTD Return

−48.57%

1Y Return

−32.01%

RSI (14)

25.8

vs 50D SMA

−24.43%

vs 200D SMA

−20.30%

Capital & dividendView details →

Debt/Equity

5.26x

Current Ratio

5.35x

Quick Ratio

4.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.16

EPS Surprise

−3.23%

Beats (12Q)

3/12

Next Q EPS Est

−$0.06

Avg Surprise (4Q)

−139.67%

Rev Surprise

8.26%

Financials snapshotView financials →

Revenue (TTM)

45.08M

Net Income (TTM)

−28.21M

Op. CF (TTM)

−29.28M

Next earningsNov 12, 2026 →

Latest newsMore news →

TriSalus Life Sciences received U.S. FDA 510(k) clearance for its TriNav Advance device, expanding its Pressure-Enabled Drug Delivery portfolio for liver embolization.27d ago

TriSalus reported a significant revenue miss and lowered its guidance during Q2 2026, citing a Salesforce reorganization and delayed FDA review of its next-generation device.74d ago

Similar companies

Rainmed Medical Limited02297.HK Profound Medical Corp.PROF RxSight, Inc.RXST Treace Medical Concepts, Inc.TMCI Standard BioTools Inc.LAB Movano Inc.MOVE Find similar companies →

Latest newsMore news →

TriSalus Life Sciences received U.S. FDA 510(k) clearance for its TriNav Advance device, expanding its Pressure-Enabled Drug Delivery portfolio for liver embolization.27d ago TriSalus reported a significant revenue miss and lowered its guidance during Q2 2026, citing a Salesforce reorganization and delayed FDA review of its next-generation device.74d ago TriSalus Life Sciences announced its financial results for the quarter ended June 30, 2026, reporting year-over-year and sequential growth.74d ago